论文部分内容阅读
目的:探讨对慢性髓细胞白血病(CML)患者行伊马替尼治疗的安全性和有效性。方法:将2015年2月~2016年2月甘肃省人民医院收治的48例CML患者作为研究对象,回顾性分析所有患者的细胞遗传学、血液学以及发生不良反应的几率。结果:所有患者经过回访,①有效性评价:血液学缓解率为45例(93.75%),3月微小细胞遗传学反应为36例(75.00%),6月微小细胞遗传学为15例(31.25%),部分细胞遗传学反应为26例(54.17%),12月完全细胞遗传学为34例(70.83%)。其中5例进展为加速期CML,经过一段时间的加量治疗后恢复为慢性期CML。②不良反应:发生5级非血液学不良反应事件为0,发生3级~4级不良反应几率为27例(56.25%),并未发生3级-4级的非血液学不良反应。结论:对慢性期CML患者行伊马替尼治疗,不仅能够提高患者血细胞遗传学和血液学的缓解率,同时,还能够降低发生3级~4级非血液学以及血液学的几率,是一种利于患者所接受的治疗手段。
Objective: To investigate the safety and efficacy of imatinib in patients with chronic myeloid leukemia (CML). Methods: Forty-eight CML patients admitted to People’s Hospital of Gansu Province from February 2015 to February 2016 were retrospectively analyzed for the cytogenetics, hematology and incidence of adverse reactions in all patients. Results: All patients were followed up. ①Evaluation of efficacy: The hematological response rate was 45 (93.75%), the rate of cytogenetic response in March was 36 (75.00%), the rate of cytogenetics in June was 15 %), Partial cytogenetic response was 26 cases (54.17%), December complete cytogenetics was 34 cases (70.83%). Among them, 5 cases progressed to accelerated phase CML and recovered to chronic phase CML after treatment for a period of time. ② Adverse reactions: grade 5 non-hematologic adverse events were 0, grade 3 to 4 adverse reactions occurred in 27 cases (56.25%), and grade 3 to 4 non-hematologic adverse reactions did not occur. CONCLUSIONS: Imatinib treatment in patients with chronic CML not only improves hematologic and hematologic remission rates but also reduces the incidence of non-hematologic and hematological grade 3 to 4 disease Benefit to patients for treatment.